



PRESS RELEASE

DISCLOSURE OF CHANGE IN SHARE CAPITAL PURSUANT TO ARTICLE 85-bis OF THE ISSUER REGULATIONS AND ARTICLE 2.6.2. PARAGRAPH 1 LETTER A) OF THE REGULATIONS OF BORSA ITALIANA S.P.A.

Capua, 8 May 2015 – Pierrel S.p.A. discloses the new composition of its share capital (fully subscribed and paid) arising from the full subscription of the capital increase that was divisible and paid as decided by the Board of Directors on 18 March 2015 and recorded in the Company Register of Caserta on 7 May 2015, in partial exercise of the delegation conferred pursuant to Article 2443 of the civil code to the Extraordinary Meeting of 12 November 2011, and the consequent issue of 4,916,279 new Pierrel S.p.A. ordinary shares with no nominal value.

The certification of the completion of the capital increase pursuant to Article 2444 of the civil code was filed with the Company Register of Caserta on 7 May 2015.

Below is a summary of the current composition of the share capital compared to the previous share capital:

	<i>Current share capital</i>		<i>Previous share capital</i>	
	<i>Euro</i>	<i>No of shares</i>	<i>Euro</i>	<i>No of shares</i>
Totals of which:	11.598.506,75	54.293.573	11.352.692,80	49.377.294
Ordinary shares with full rights from 1 January 2015	11.598.506,75	54.293.573	11.352.692,80	49.377.294
Current coupon number: 05				

* * *

Pierrel S.p.A. is a global supplier to the pharmaceutical, biopharmaceutical and life science industries, specialising in the discovery of medicinal product candidates and the repositioning of existing drugs for new therapeutic indications and clinical research (TCRDO Division), pharmaceutical production (Contract Manufacturing Division) and the development, registration and licensing of new drugs and medical devices (Pharma Division).

Pierrel Group is listed on the MTA exchange which is organised and managed by Borsa Italiana and boasts over 60 years' experience in the pharmaceutical sector, being one of Europe's leading producers of local and dental anaesthetics. The TCRDO Division, working across Europe and the US, is recognised internationally for its research and development into tech based clinical research innovations with its Drug Repositioning and Repurposing System ("DRR2.0") and Integrated Clinical Development Services ("ICDS") for the pharmaceutical, biotechnology and biomedical industries. The parent company of the TCRDO Division (**THERAMetrics holding AG**, listed in the Swiss stock exchange) holds the innovative interactive **DRR2.0** platform, which runs on a database of 23 million scientific publications (being virtually all of those available in the field of biomedical literature), of over 4,900 drugs and of 9,400 illnesses. With this data, never before collected in one place and stored in the cloud, the Search and Match algorithm can show a researcher not only the candidate drug but also a detailed road map with indications of possible second medical use. The database can be accessed by molecule or by illness. Pierrel also has a production unit in Capua, close to Naples, Italy, that has been authorised by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for the aseptic production of injectable medicines. The subsidiary Pierrel Pharma S.r.l. has registered and distributes the Orabloc® dental anaesthetic in Canada, US, Russia and Europe.

The registered office of Pierrel S.p.A. is in Capua (CE), Italy.

For further information:

Pierrel S.p.A.
Investor Relations

Global Consult S.r.l.
Media Relations



Dr Raffaele Petrone

e-mail:

investor.relations@pierrelgroup.com

tel. +39 0823 626 111

fax +39 0823 626 228

Rossana Del Forno

e-mail:

areacomunicazione@globalconsultsrl.com

tel. +39 333 6178665